Author Correction: Integrin β3/Akt signaling contributes to platelet-induced hemangioendothelioma growth

Correction to: Scientific Reports 10.1038/s41598-017-06927-0, published online 25 July 2017

This Article contains an error in Figure 6, where the Control and Platelet images for Control siRNA and Integrin beta 3 siRNA groups were mistakenly taken from the same original image file in panel (d).

The correct Figure 6 and accompanying legend appear below.

Figure 6.

The integrin β3/Akt signaling contributed to platelet-induced EOMA cell proliferation. (a) EOMA cells were transfected with control or integrin β3 siRNA for 4 days, and then treated with platelets for another 72 hours. The cell viability was examined using the CCK8 assay. (b) The EOMA cells were incubated with indicated concentrations of Akt inhibitor GSK690693 for 72 hours. GSK690693 treatments with 1 and 2 μM did not significantly affect EOMA cell survival. (c) EOMA cells were pre-treated with Akt inhibitor GSK690693 for 3 hours, and then incubated with platelets for another 72 hours. The cell viability was examined using the CCK8 assay. (d) EOMA cells were either transfected with control or integrin β3 siRNA for 4 days, or pre-treated with GSK690693 for 3 hours, and then incubated with platelets for another 48 hours. The cell proliferation was assessed via the EdU assay. Scale bar, 60 μm. n = 3–5, one-way or two-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

Additionally, an incorrect email address for author Xiao-Ming Chen is quoted. Correspondence and requests for materials should be addressed to cxm@wmu.edu.cn.